Interactive Features

Test Your Knowledge

Quiz: Which Treatment Received FDA Approval for Metastatic Urothelial Carcinoma?

11/03/2020

What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?

What treatment was approved by...

11/03/2020

Oncology

Test Your Knowledge

Quiz: Does Pembrolizumab Yield Promising Results in Advanced Urothelial Cancer?

09/10/2020

True or False: Pembrolizumab provided a durable clinical response in cisplatin-ineligible patients with advanced urothelial carcinoma and is associated with prolonged OS.

True or False: Pembrolizumab...

09/10/2020

Oncology

Test Your Knowledge

Quiz: Is Enfortumab Vedotin an Effective Therapy for Metastatic Urothelial Cancer?

06/22/2020

True or False: Enfortumab vedotin monotherapy has not been shown to yield durable responses in patients with metastatic urothelial cancer.

True or False: Enfortumab...

06/22/2020

Oncology

Test Your Knowledge

Quiz: Is Teratoma a Prognostic Factor in Testicular Germ Cell Tumors?

05/05/2020

True or false: Teratoma is a prognostic factor in patients with metastatic testicular germ cell tumors.

True or false: Teratoma is a...

05/05/2020

Oncology

Test Your Knowledge

Quiz: Adjuvant vs Neoadjuvant Chemo for Muscle-Invasive Bladder Cancer

03/06/2020

True or False: Patients with muscle-invasive bladder cancer have increased overall survival with adjuvant versus neoadjuvant chemo.

True or False: Patients with...

03/06/2020

Oncology

Test Your Knowledge

Quiz: Adding THOLR or TUR to Epirubicin After Surgery for Bladder Cancer

02/12/2020

True or False: Combining transurethral holmium laser resection or transurethral electrocision with intravesical epirubicin within 2 weeks of surgery has been shown to be safe and effective for patients with bladder cancer.

True or False: Combining...

02/12/2020

Oncology

Test Your Knowledge

Quiz: Can Education and Rehab Improve QoL in Muscle Invasive Bladder Cancer?

01/06/2020

True or False: Education and rehabilitation programs have shown no benefits in the post-surgery management of patients with muscle-invasive bladder cancer.

True or False: Education and...

01/06/2020

Oncology

Test Your Knowledge

Quiz: Effect of New Long Non-Coding RNA on Bladder Cancer

12/20/2019

Study findings suggest that the novel long non-coding (lnc)RNA KMU15 could _____ the proliferation and progression of bladder cancer.

Study findings suggest that the...

12/20/2019

Oncology

Test Your Knowledge

Quiz: Urinary Calprotectin as a Bladder Cancer Tumor Marker

12/20/2019

True or False: Urinary calprotectin cannot be used as a specific tumor marker for bladder cancer.

True or False: Urinary...

12/20/2019

Oncology

Test Your Knowledge

Quiz: Does YAP1/mTOR Interaction Inhibit Bladder Cancer Progression?

12/19/2019

True or False: The interaction between YAP1 and mTOR slows down disease progression in patients with bladder cancer.

True or False: The interaction...

12/19/2019

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology